CompletedPhase 2ACTRN12616000469415
Effects of noradrenergic and antimuscarinic agents on upper airway muscle activity during sleep
Effects of noradrenergic and antimuscarinic agents on upper airway muscle activity during sleep in healthy adults
Sponsor
Neuroscience Research Australia (NeuRA)
Enrollment
10 participants
Start Date
Apr 15, 2016
Study Type
Interventional
Conditions
Summary
To determine if sleep-related reductions in upper airway muscle activity during sleep will be higher after a combined noradrenergic/antimuscarinic intervention compared to placebo.
Eligibility
Sex: Both males and femalesMin Age: 18 YearssMax Age: 65 Yearss
Inclusion Criteria1
- Healthy men and women aged 18-65 years who do not have any known sleep disorders
Exclusion Criteria4
- Women lactating, pregnant or of childbearing potential who are not willing to avoid becoming pregnant during the study.
- Patients with any other medical condition which may interfere in the evaluation of the study.
- Patients with a previous history of addiction to alcohol or drugs.
- Patients taking medications known to affect sleep or muscle activity.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Reboxetine 4mg + Hyoscine 20mg taken orally just prior to sleep (single dose)
1 week washout
Reboxetine 4mg + Hyoscine 20mg taken orally just prior to sleep (single dose) 1 week washout
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12616000469415